SkyAI intends to purchase up to 95% of each class of its outstanding common stock, cash pre-funded warrants, cryptocurrency pre-funded warrants and strategic advisor warrants Purchase price represents a 65% premium above SkyAI’s closing share price on October 9, 2026, and an over 100% premium to the 60-day volume-weighted average price The Board rejects Forward Industries’ latest unsolicited proposal after determining it undervalues SkyAI and is not in the best interests of shareholders NEW YORK, Oct. 11, 2026 (GLOBE NEWSWIRE) — SkyAI, Inc. (Nasdaq: SKYA) (“SkyAI” or the “Company”) today announced that it intends to commence a tender offer (the “Offer”) to purchase up to 95% of each class of its outstanding common stock, cash pre-funded warrants, cryptocurrency pre-funded warrants and strategic advisor warrants at a purchase price...

Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors NANJING, China, Oct. 12, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its core product opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, for the first-line treatment of advanced or metastatic biliary tract cancer (BTC). This is the second FDA Fast Track Designation for opamtistomig, following its previous designation in extrapulmonary neuroendocrine carcinoma (EP-NEC). The BTC designation was granted just nine days after submission, reflecting the urgency of addressing unmet medical needs in this patient population and the potential clinical value...

BEIJING, Oct. 11, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for ICP-B161, a bispecific antibody targeting TL1A and IL-23p19, for the treatment of autoimmune diseases, including inflammatory bowel disease (IBD). ICP-B161 is InnoCare’s fifth novel drug candidate to enter clinical development in 2026. With its novel molecular design, ICP-B161 delivers an extended half‑life, which allows for less frequent dosing and supports subcutaneous administration, making it a differentiated long-acting bispecific antibody. By simultaneously targeting...

PERTH, Australia, Oct. 11, 2026 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) advises that it will release its quarterly results for the period ended 30 September 2026 on the ASX platform on Wednesday, 14 October 2026. The announcement will also be available on the SEDAR+ platform. The Company will hold a conference call on Wednesday, 14 October 2026, at 11.00am AEDT1 (Tuesday, 13 October 2026, at 8.00pm EDT2). To participate in the live teleconference, please register at the link below: Paladin September 2026 Quarterly Results Conference Call Please note it is recommended to log on at least five minutes before the scheduled commencement time to ensure you are registered in time for the start of the call. A recording of the call will be available on Paladin’s website shortly after...

SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) — First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT. A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events. The data will be provided in a morning press release and presented during the webcast. A replay of the webcast will be available for at least 30 days following the event. About...

– In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically significant 18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation, and diuretic intensification versus tafamidis (HR 0.82; 95% CI 0.73-0.93; p

•    Stellantis offered an exclusive preview of six of the nine concept cars set to debut at the Paris Motor Show, October 12-18  •    Alfa Romeo, Citroën, DS Automobiles, FIAT, Opel and PEUGEOT showcased how creativity and innovation enable emotion, serve people and enhance freedom of choice •    Stellantis Chairman John Elkann, CEO Antonio Filosa andEnlarged Europe COO Emanuele Cappellano highlightedhow FaSTLAne 2030 strategic plan is translating into tangible results, through technologies, products and  innovations with the customer at the center •    Gilles Vidal, Head of Design, Enlarged Europe, presented the concept cars, illustrating how Stellantis is challenging conventions and accelerating towards the future •    “The Night Before” offered a preview of Stellantis’ bold presence at the Paris Motor Show, featuring the exhibition’s...

– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of colorectal cancer remained consistent with test’s first version, achieving 80.4% sensitivity at 90% specificity – BRISBANE, Calif., Oct. 11, 2026 (GLOBE NEWSWIRE) — Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based tests, today announced the company will present late-breaking data on an updated version of its SimpleScreen™ CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville. Freenome conducted a pivotal clinical validation study to assess the performance of assay and algorithm improvements for the updated version of SimpleScreen CRC....

– Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1 – 100% of participants who received encaleret reported improvements in at least one ADH1 symptom compared to 46% of participants who received standard of care – Improvements in ADH1-related impacts on daily functioning were also more frequently reported with encaleret compared to standard of care – The FDA has accepted BridgeBio’s NDA for encaleret in ADH1 and granted Priority Review, with a PDUFA target action date of May 8, 2027; the Company also submitted an MAA to the EMA – The first participant was dosed in RECLAIM-HP, the registrational Phase 3 study of encaleret in adults and adolescents with chronic hypoparathyroidism PALO ALTO, Calif., Oct. 11, 2026 (GLOBE NEWSWIRE) —...

HANGZHOU, China, Oct. 11, 2026 (GLOBE NEWSWIRE) — Geely Auto Group today announced the market launch of its first electrified off-road SUV, named Zhanjian 700 in China, and the first production model built on its dedicated GTA architecture for electrified off-road vehicles.Positioned as an AI-powered all-terrain SUV, the model combines off-road capability, electrified performance, intelligent vehicle control, safety and a versatile interior for both daily driving and demanding terrain. It addresses a longstanding compromise in the rugged SUV segment: choosing between off-road capability and on-road comfort, or between performance and efficiency. By integrating architecture, powertrain and chassis control as one system, Geely delivers capability without sacrificing everyday usability. A purpose-built foundation for city road and...